Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Temporary Equity And Stockholders' (Deficiency) Equity (Unaudited)

v3.8.0.1
Condensed Consolidated Statement of Changes in Temporary Equity And Stockholders' (Deficiency) Equity (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($)
Series B Convertible Redeemable Preferred Stock [Member]
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Total
Balance beginning at Dec. 31, 2016 $ 429,153 $ (14,070) $ 80,102,189 $ (10,459,242) $ (67,631,569) $ 2,426,461
Balance beginning, shares at Dec. 31, 2016 42,915,379 4,411        
Series B preferred stock issued for cash $ 6,352,319
Series B preferred stock issued for cash, shares 635,233            
Common stock issued for cash, net of issuance costs of $4,500 $ 225 40,275 40,500
Common stock issued for cash, net of issuance costs of $4,500, shares 22,500          
Common stock issued in satisfaction of deferred revenue $ 622 123,917 124,539
Common stock issued in satisfaction of deferred revenue, shares 62,270          
Exchange of 8% notes for Series B preferred stock $ 1,267,324
Exchange of 8% notes for Series B preferred stock, shares 126,700            
Stock-based compensation: Common stock issued under 401(k) profit sharing plan $ 370 73,498 73,868
Stock-based compensation: Common stock issued under 401(k) profit sharing plan, shares 36,933          
Options and warrants 462,036 462,036
Dividends (60,515) (60,515)
True-up to transfer agent's records $ (4) 4
True-up to transfer agent's records, shares (373)          
Net loss (5,612,632) (5,612,632)
Other comprehensive loss (262,187) (262,187)
Balance ending at Sep. 30, 2017 $ 7,619,643 $ 430,366 $ (14,070) $ 80,741,404 $ (10,721,429) $ (73,244,201) $ (2,807,930)
Balance ending, shares at Sep. 30, 2017 761,933 43,036,709 4,411